- Akston Biosciences: “Akston Biosciences Announces Positive Top-Line Data from Phase II Study of COVID-19 Vaccine in the Netherlands” (Dec. 22, 2021)
- SEQENS: “Change in SEQENS’ shareholding structure: SEQENS is now stronger, more focused and positioned as one of the world’s leading players in pharmaceutical solutions and specialty ingredients” (Dec. 17, 2021)
- Hebrew SeniorLife: “Study Shows that Consumption of a Pro-Inflammatory Diet is Associated with Increased Odds of Frailty Onset in Middle-Aged and Older Adults: Regularly Eating Nutrients Such as Dietary Fiber and Dietary Antioxidants May Prevent Older Adults from Becoming Frail: (Dec. 7, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife Named a Boston Globe Top Place to Work 2021:Nonprofit Senior Care Organization Ranked 24th of the Top Largest Companies” (Dec. 2, 2021)
- Akston Biosciences: “Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine” (Nov. 20, 2021)
- Vortex International: “Vortex International Launches Dream Tunnel™, World’s First Fully Immersive Aquatic Attraction at IAAPA Expo: Experience Dream Tunnel™ at Booth #934 at the IAAPA Expo from Nov. 16-19 in Orlando” (Nov. 15, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife Named a Top Place to Work for 2021 by The Boston Globe: Nonprofit Senior Care Organization Ranked 24th of the Top Largest Companies” (Nov. 5, 2021)
- Hebrew SeniorLife: “Solarea Bio Teams up with Hebrew SeniorLife Investigators on a Newly Awarded U.S. National Academy of Medicine Catalyst Grant; Healthy Longevity Initiative Grant Awarded to Study the Mycobiome as a Novel Class of Probiotics to Target Inflammaging” (Nov. 4, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife Launches ‘The Age of Opportunity’: Campaign Addresses Urgent and Advancing Needs of Seniors from All Walks of Life” (Nov. 2, 2021)
- Lumen Technologies: “Lumen and Cisco expand their partnership to help businesses embrace the future of work with advanced communication and collaboration solutions” (Oct. 25, 2021)
- Hebrew SeniorLife: “Social Determinants of Health Provide Better Understanding of Brain Vulnerability to Delirium: Hebrew SeniorLife Study Advances an Understanding of the Factors that Improve Health Outcomes in Older Adults” (Oct. 25, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife’s 8th Annual EngAGE Brings Entertainment with Mavis Staples and Mandy Patinkin: Raising Funds to Change the Way We Age for Future Generations” (Oct. 7, 2021)
- Seqens CDMO NA: “Seqens Appoints Bob Huang Managing Director of North American CDMO Operations:Sanofi Veteran to Expand Seqens’ Global Footprint, Build Upon Strong Local Presence” (Sept. 14, 2021)
- Regis College: “Regis College Offers Tuition Discounts to Hebrew SeniorLife Employees” (Sept. 10, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife to Offer New Tuition Discount Benefit to All Employees; Agreements with Drexel, Quinnipiac, Regis, and Other Higher Ed Institutions Expand Learning Opportunities for Employees” (Sept. 10, 2021)
- Akston Biosciences: “Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine” (Aug. 5, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife Makes COVID-19 Vaccination a Condition of Employment: Effective October 1, 2021, Requirement Designed to Protect the Health and Safety of Patients, Residents, and Employees” (July 26, 2021)
- Hebrew SeniorLife: “Hebrew SeniorLife Receives The John A. Hartford Foundation 2021 Business Innovation Award: n4a’s Aging and Disability Business Institute Recognized Hebrew SeniorLife for its Innovative Program that Integrates Health Care Services and Housing” (July 21, 2021)
- Akston Bioscience: “Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale;New data shows protein-based AKS-452 vaccine is shelf-stable for six months at 25° C (77° F)“ (July 21, 2021)
- Akston Bioscience: “Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate” (July 8, 2021)
- Akston Biosciences: “Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine” (April 12, 2021)
- Lumen Technologies: “Lumen Technologies to host Analyst Day on Wednesday, April 7” (March 23, 2021)
- The University Medical Center Groningen: “UMCG is investigating candidate vaccine against corona and is looking for volunteers. This is the AKS-452 vaccine from Akston Biosciences in the United States” (March 18, 2021)
- Akston Biosciences: “Akston Biosciences Signs Licensing Agreement with Dechra Pharma for AKS-425c, a Once-a-Week Insulin Therapy for Cats Follows earlier agreement between Akston and Dechra for AKS-321d, a once-a-week insulin therapy for dogs” (Feb. 9, 2021)
- Akston Biosciences: “Akston Biosciences and LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine A vaccine for everywhere and everyone in the world, AKS-452 is stable for weeks at room temperature, inexpensive to produce, and suitable for both first-time and booster vaccination” (Jan. 5, 2021)
Tagged: 2021
